Details for New Drug Application (NDA): 088850
✉ Email this page to a colleague
NDA 088850 describes HYDROFLUMETHIAZIDE, which is a drug marketed by Par Pharm, Watson Labs, and Usl Pharma, and is included in six NDAs. Additional details are available on the HYDROFLUMETHIAZIDE profile page.
The generic ingredient in HYDROFLUMETHIAZIDE is hydroflumethiazide; reserpine. There are two drug master file entries for this compound. Additional details are available on the hydroflumethiazide; reserpine profile page.
The generic ingredient in HYDROFLUMETHIAZIDE is hydroflumethiazide; reserpine. There are two drug master file entries for this compound. Additional details are available on the hydroflumethiazide; reserpine profile page.
Summary for 088850
| Tradename: | HYDROFLUMETHIAZIDE |
| Applicant: | Par Pharm |
| Ingredient: | hydroflumethiazide |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 088850
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 50MG | ||||
| Approval Date: | May 31, 1985 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
